Key Drivers
- Cash Generation
- Balance Sheet
- Cost Pressure
AIAI Summary
HRMY is now a profitable, cash-generative specialty pharma name with real growth, but the investment case remains capped by heavy WAKIX concentration, access friction, and looming generic/legal risks, so it looks more like a durable hold than a clear buy until diversification or operating leverage improves.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Balance Sheet
- •Cost Pressure
HRMY shows strong profitability, robust cash generation, and a solid balance sheet, but high operating costs, share-based comp, and heavy investment are tempering quarterly margin momentum.
Price Behavior
Key Price Behavior Insights:
- •Rally faded
- •Range-bound trade
- •Key resistance
HRMY is still range-bound after a sharp early-May rally, but fading momentum means it needs to reclaim $31-$32 to stay constructive, while a drop below $30 would weaken the setup.
Sharp rally from about $29.53 to $32.78, then a steady pullback since the early-May peak
Sentiment & News
Key News Insights:
- •EPS Miss
- •WAKIX Growth
- •Guidance Reaffirmed
Harmony Biosciences posted Q1 EPS below expectations but delivered 17% WAKIX revenue growth and reaffirmed 2026 revenue guidance above $1 billion, keeping the outlook constructive despite near-term earnings pressure.
The stock may face short-term pressure from the earnings miss, but solid revenue growth and unchanged full-year guidance support a cautiously positive medium-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings